Tasigna 150 mg (40 capsules) Novartis

Tasigna 150 mg (40 capsules) – Novartis Pharma AG

Overview

Tasigna 150 mg (nilotinib) is an oral tyrosine kinase inhibitor developed by Novartis Pharma AG, Switzerland.
It is indicated for the treatment of adults and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic or accelerated phases.

Indications

• Newly diagnosed Ph+ CML in chronic phase.
• Ph+ CML resistant or intolerant to prior therapy including imatinib.

Composition and Form

• Each hard capsule contains 150 mg nilotinib (as hydrochloride monohydrate).
• Capsule: red with black imprint “NVR/BCR”.
• Pack: 40 capsules per box.

Manufacturer:
Novartis Pharma AG, Basel, Switzerland.

Mechanism of Action

Nilotinib selectively inhibits the BCR-ABL tyrosine kinase produced by the Philadelphia chromosome. This action blocks abnormal signaling and suppresses the proliferation of leukemic cells.

Dosage & Administration

• Must be taken on an empty stomach — no food for 2 hours before and 1 hour after dosing.
• Usual adult dose:
  • 300 mg twice daily (newly diagnosed CML).
  • 400 mg twice daily (resistant/intolerant cases).
• Dose adjustments only under medical supervision.

Adverse Effects

Common: rash, itching, headache, nausea, fatigue.
Serious: myelosuppression, hepatic dysfunction, QT prolongation, edema, muscle pain.
Regular ECG and blood monitoring are recommended.

Storage

Store below 30 °C, in the original package, protected from moisture and light. Keep out of reach of children.